Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumorsDavid H. Henry, Howard Yeh, Saroj Vadhan‐Raj et al.|Supportive Care in Cancer|2013Cited by 182
Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancerInês Gomes, Sandra Casimiro, Raquel Cruz-Duarte et al.|Oncotarget|2020Cited by 27